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Poster Session II S327had worse engraftment compared to congenic wildtypemice. In con-
clusion, both, vacating of HSC niche space, and the effects of host
regulatory cells, that are activated during the TLI procedure appear
critical to permit donor HSC engraftment post-TLI/ATG. The dy-
namics of engraftment after TLI/ATGare unique. Further studies to
define the exact roles of host Tregs and NKT cells in engraftment
after TLI/ATG and other conditioning modalities are underway.330
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Background: Hematopoietic stem cell transplantation (HSCT) is
the treatment of choice for severe combined immunodeficiency
(SCID). There remains debate on whether to pre-condition with
chemotherapy prior to infusion of stem cells.We aimed to determine
the long-term progress of classic SCID patients who had undergone
HSCT infusion at our centre, with respect to clinical outcome and
immune comparing outcome based on transplant at \3 or .3
months of age, and molecular diagnosis.
Methods: A retrospective case notes review of patients undergoing
a first HSCT infusion for classic SCID from 01/1995 to 02/2011,
surviving. 2 months. Patients with previous HSCT were excluded.
Parameters analyzed included clinical outcome, chimerism, lympho-
cyte subsets including recent thymic emigrants, specific antibody
levels and Ig replacement. Statistical analysis was performed using
c 2 (Fisher exact test) and nonparametric wilcoxon rank sum. A 2-
sided p value\ 0.05 was considered significant.
Results: Twenty seven of 100 patients with SCID treated fulfilled
the study criteria; 10 had ADA deficiency, 7 had T-B-NK+ pheno-
type, 8 had CgC/JAK3 SCID, and 2 had other forms of SCID. 12
were transplanted\ 3 months of age, median age at HSCT was 3
months (range 0-8 months). Twenty had infection at diagnosis, all
. 3 months. Eleven had MSD, 1 MMSD, 5 MFD, 3 MMFD, 6
MUD, 1MMUD.Twenty receivedGvHDprophylaxis. Median fol-
low up was 80 months (2-187). Seven developed grade II-IV GvHD,
3 grade III. Five were re-transplanted, 2 received boost infusion for
poor engraftment (1 CgC, 1 T-B-NK+), 3 received a conditioned
HSCT (3 T-B-NK+). TRMwas 11% (1 ADA, 2T-B-NK+). Neuro-
logical and autoimmune complications were more common in the
ADA and T-B-NK+ groups. Recent thymic emigrants were most
commonly present in the CgC/JAK3 and ADA groups, and absent
from the T-B-NK+ group. The ADA group had the most complete
donor chimerism including myeloid chimerism, T-B-NK+ SCID
only achieved donor T cell chimerism. Most ADA patients discon-
tinued IVIG, compared to none with T-B-NK+ SCID.
Conclusion: HSCT infusion is an effective treatment for SCID.
Best results are obtained if transplanted\ 3 months of age. Estab-
lishment of donor B cell chimerism may require additional therapies
to achieve engraftment within the stem cell niche in all but ADA
SCID.331
DECITABINE IN COMBINATION WITH DONOR LYMPHOCYTE INFUSION
AS SALVAGE THERAPY FOR RELAPSED AML POST-ALLOGENEIC STEM
CELL TRANSPLANTATION
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Prognosis is extremely poor for AMLpatients who relapse after al-
logeneic stem cell transplantation. Donor Lymphocyte infusions
(DLI) can be used to salvage these patients with complete responserates reported to be 10-15% with an associated 40-60% chance of
developing clinically significant GVHD. The mechanism by which
DLI results in clinical responses is thought to be a T-cell mediated
process. Data suggest that DLI normalizes the T-cell receptor rep-
ertoire and expands the anti-leukemic cell population. Hypomethy-
lating agents, which appear to foster the graft versus leukemia
phenomenon, were combined with DLI in attempt to enhance the
graft versus leukemia effect.
We report ten AML patients who received Decitabine +/- Eto-
poside with incremental DLI as salvage after relapse from alloge-
neic stem cell transplantation during the years 2007-2010. These
patients were between the ages of 26- 73 years. Six patients had
de novo AML. Three patients were transformed from MDS, and
one from essential thrombocythemia. Eight patients had reduced
intensity conditioning regimens. Two patients received a fully ab-
lative preparative regimen. Average time to progression post trans-
plant was 17 months.
Patients received Decitabine at 20mg/m2 for 5 - 10 days, some in
combination with Etoposide for 3-5days for disease control. Patients
received 1-4 courses of treatment approximately every 28 days with
DLI between days 14-21. Two patients who progressed while receiv-
ing Decitabine/Etoposide received Clofarabine at 20-52mg/m2 for 5
days, with subsequent DLI. Cell dose ranged from 1.27 to 31.7
CD3+ cells / kg. Two patients received a mobilized DLI.
Six out of ten patients regained full chimerism. One patient who
relapsed with extra medullary disease never lost his graft. Seven out
of ten patients achieved a complete remission. Only one patient de-
veloped Grade 2 GVHD of the skin. Overall survival in these pa-
tients after relapse from allogeneic transplantation was 10.8
months.
The combination of Decitabine and DLI is a well tolerated outpa-
tient therapeutic option for patients with relapsed AML post alloge-
neic stem cell transplantation. The majority of patients regained full
chimerism and achieved complete remission with little or no
GVHD.332
IS THE USE OF 9/10 HLA UNRELATED DONORS STILL ACCEPTABLE IN
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HEMATOLOGICAL MALIGNANCIES? COMPARISON WITH TRANSPLANTS
FROM 10/10 HLA UNRELATED DONORS AND SIBLINGS
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Tedone, N., Ducastelle, S., Barraco, F., Chelghoum, Y., Thomas, X.,
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To evaluate the outcome of allo-HSCT from 9/10 HLA mis-
matched unrelated donors compared to those from 10/10HLA iden-
tical unrelated donors and siblings; we retrospectively studied the
outcome of 213 patients who received allo-HSCT for different he-
matological malignancies, 121 (57%) from HLA identical siblings,
63 (29%) from 10/10 HLA identical unrelated donors and 29
(14%) from 9/10 HLA mismatched unrelated donors between
2006 and 2011 at our institution. The different patient characteris-
tics and figures will be provided in the future during the presentation.
After HSCT, engraftment was significantly lower in the 9/10 HLA
group (90%) than in the 10/10 HLA group (95%) than in the sibling
group (99%), (p5 0.03); the cumulative incidence of acute GVHD.
5 2 at 3 months was 32% (23-41), 20% (15-26) and 27% (23-32) re-
spectively; the cumulative incidence of extensive chronic GVHD at
one year was 21% (13-30), 9% (5-13) and 17% (14-21) for the 3
groups respectively. After a median follow-up of 8 months (0-54)
in the 9/10 HLA group, 10 months (0-60) in the 10/10 HLA group
and 18 months in the siblings group, the median OS was 10 months
(5-21), 18months (11-NR) and 60months (31-NR) respectively with
a 2-years probability of 19% (8-44), 43% (31-59) and 63% (54-74)
respectively. There was a higher but not significant relapse incidence
at one year in the 9/10 HLA group compared to other groups while
the TRM was significantly higher with a cumulative incidence at 1
year of 45% (35-55) vs. 33% (27-39) for 10/10 and 12%(9-15) for
siblings, (p\0.001). In multivariate analysis, OS was negatively af-
fected by unrelated donors [9/10 HR 5 5 (2.7-10), p 5 0.0001;
10/10 HR 5 2 (1.2-4), p 5 0.01], female donors [HR 5 2 (1.4-4),
p 5 0.03] and disease status\CR1 or\chronic phase 1 [HR 5 3
(1.4-6), p 5 0.003]; while the TRM was negatively affected by
